Zolata Hamidreza, Afarideh Hossein, Davani Fereydoun Abbasi
1 Energy Engineering and Physics Faculty, AmirKabir University of Technology , Tehran, Iran .
2 Rays Application Department, Shahid Beheshti University of Tehran , Tehran, Iran .
Cancer Biother Radiopharm. 2016 Nov;31(9):324-329. doi: 10.1089/cbr.2016.2068.
By using radio-labeled multifunctional superparamagnetic iron oxide nanoparticles (SPIONs) and an alternating magnetic field (AMF), we carried out targeted hyperthermia, drug delivery, radio-immunotherapy (RIT), and controlled chemotherapy of cancer tumors. We synthesized and characterized Indium-111-labeled, Trastuzumab and Doxorubicin (DOX)-conjugated APTES-PEG-coated SPIONs in our previous work. Then, we evaluated their capability in SPECT/MRI (single photon emission computed tomography/magnetic resonance imaging) dual modal molecular imaging, targeting, and controlled release. In this research, AMF was introduced to evaluate therapeutic effects of magnetic hyperthermia on radionuclide-chemo therapy of HER2 cells and tumor (HER2)-bearing mice. In vitro and in vivo experiments using synthesized complex were repeated under an AMF (f: 100 KHz, H: 280 Gs). Instead of an intra-tumor injection in most hyperthermia experiments, SPIONs were injected to the tail vein, based on our delivery strategies. For magnetic delivery, we held a permanent Nd-B-Fe magnet near the tumor region. The results showed that simultaneous magnetic hyperthermia enhanced SKBR3 cancer cells, killing by 24%, 28%, 33%, and 80% at 48 hours post-treatment for treated cells with (1) bare SPIONs; (2) antibody-conjugated, DOX-free, surface-modified SPIONs; (3) In-labeled, antibody-conjugated surface-modified SPIONs; and (4) In-labeled, antibody- and DOX-conjugated surface-modified SPIONs, respectively. Moreover, tumor volume inhibitory rate was 85% after a 28 day period of treatment. By using this method, multimodal imaging-guided, targeted hyperthermia, RIT, and controlled chemotherapy could be achievable in the near future.
Cancer Biother Radiopharm. 2016-11
Mater Sci Eng C Mater Biol Appl. 2017-1-1
Cancer Biother Radiopharm. 2017-12
Cancer Nanotechnol. 2023
Int J Nanomedicine. 2020-11-5